Grufity logoGrufity logo

ANTX

Market Closed

AN2 Therapeutics, Inc.

ANTX Alerts

ANTX Stock Price

RSI Chart

Valuation

Market Cap

172.7M

Price/Earnings

-4.86

Price/Sales

338.6

Price/Cashflow

-5.29

Price/Sales

Profitability

Return on Equity

-30.68%

Return on Assets

-29.62%

Fundamentals

Revenue

Revenue (TTM)

961.3K

Revenue Y/Y

1.8K%

Revenue Q/Q

104.39%

Earnings

Earnings (TTM)

-38.8M

Earnings Y/Y

-63.32%

Earnings Q/Q

-12.05%

Price Action

Financial Health

Current Ratio

28.17

Investor Care

Shares Dilution (1Y)

636.64%

Diluted EPS (TTM)

-5.47

Financials for AN2 Therapeutics

Income Statement (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q32021Q2
Revenue157.5%961373895634
Operating Expenses19.4%39,71533,26426,15118,64014,096
  S&GA Expenses24.1%12,0369,6966,0473,8482,598
  R&D Expenses11.8%26,34523,56819,77114,45910,998
Net Income-17.8%-38,818.67-32,957.33-26,140.00-18,664.00-14,110.00
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q4
Assets-8.3%11012012165-
  Current Assets-8.2%10711712060-
    Cash Equivalents-29.1%29418312-
Liabilities6.8%4453-
  Current Liabilities6.8%4453-
Shareholder's Equity-8.9%106116115-47.41-
  Retained Earnings-17.0%-77.88-66.54-56.42-47.38-
  Additional Paid-In Capital0.7%184183172--
Shares Outstanding0%1919193-
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q32021Q2
Cashflow From Operations-22.8%-34.43-28.04-22.25-15.32-13.60
  Share Based Compensation42.8%43110
Cashflow From Investing14.4%-37.10-43.3314-27.94-98.57
Cashflow From Financing0.3%949484106159

Risks

What is the probability of a big loss on ANTX?

55.6%


Probability that AN2 Therapeutics stock will be more than 20% underwater in next one year

55.6%


Probability that AN2 Therapeutics stock will be more than 30% underwater in next one year.

55.6%


Probability that AN2 Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ANTX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if AN2 Therapeutics was unfortunately bought at previous high price.

Returns

Cumulative Returns on ANTX

Which funds bought or sold ANTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Aurora Investment Counsel
SOLD OFF
-100
-2,217,000
-
-%
2022-11-23
Toroso Investments, LLC
REDUCED
-1.45
-238,000
3,048,000
0.13%
2022-11-23
Eagle Bay Advisors LLC
REDUCED
-0.24
-23,821
371,000
0.23%
2022-11-23
CLIENT 1ST ADVISORY GROUP, LLC
ADDED
14.16
28,000
410,000
0.26%
2022-11-22
IHT Wealth Management, LLC
NEW
-
333,000
333,000
0.03%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
49,624,000
49,624,000
0.58%
2022-11-22
CVA Family Office, LLC
ADDED
4.6
-3,000
207,000
0.06%
2022-11-22
B. Riley Wealth Advisors, Inc.
ADDED
19.44
89,000
801,000
0.02%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-4.44
18,000
33,000
-%
2022-11-21
ST GERMAIN D J CO INC
UNCHANGED
-
-
263,000
0.02%

1–10 of 47

Latest Funds Activity

Are funds buying ANTX calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own ANTX

AN2 Therapeutics News

Yahoo Finance

AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates.18 days ago

ANTX Fair Value

Recent SEC filings of AN2 Therapeutics

View All Filings
Date Filed Form Type Document
Nov 14, 2022
4
Insider Trading
Nov 09, 2022
10-Q
Quarterly Report
Nov 09, 2022
4
Insider Trading
Nov 09, 2022
8-K
Current Report
Nov 07, 2022
4
Insider Trading
Nov 02, 2022
4
Insider Trading
Oct 28, 2022
4
Insider Trading
Oct 28, 2022
4
Insider Trading
Oct 26, 2022
4
Insider Trading
Oct 24, 2022
4
Insider Trading

Latest Insider Trading transactions for ANTX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-14
Easom Eric
SOLD
-345.92
15.04
-23
Chief Executive Officer
2022-11-10
Easom Eric
SOLD
-67,628.3
15.3248
-4,413
Chief Executive Officer
2022-11-09
Easom Eric
SOLD
-157,847
15.6114
-10,111
Chief Executive Officer
2022-11-08
Easom Eric
SOLD
-109,947
15.5842
-7,055
Chief Executive Officer
2022-11-07
Easom Eric
SOLD
-195,741
16.0404
-12,203
Chief Executive Officer
2022-11-04
Easom Eric
SOLD
-139,474
15.7991
-8,828
Chief Executive Officer
2022-11-03
Easom Eric
SOLD
-223,058
15.7472
-14,165
Chief Executive Officer
2022-11-02
Easom Eric
SOLD
-23,262.5
15.0664
-1,544
Chief Executive Officer
2022-10-31
Easom Eric
SOLD
-41,362.7
15.3879
-2,688
Chief Executive Officer
2022-10-28
Easom Eric
SOLD
-25,392.4
15.0876
-1,683
Chief Executive Officer

1–10 of 41

Eric Easom
20
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

ANTX Income Statement

2022-09-30
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating expenses:    
Research and development$ 7,428$ 5,345$ 19,759$ 10,844
Research and Development - Related Party1,000 1,000250
General and administrative3,3421,5879,0272,886
Total operating expenses11,7706,93229,78613,980
Loss from operations(11,770)(6,932)(29,786)(13,980)
Interest income4662572142
Other expense(35)(36)(49)(60)
Net loss(11,339)(6,943)(29,114)(13,998)
Accretion to redemption value and cumulative dividends on preferred stock (1,925)(1,820)(4,590)
Net loss attributable to common stockholders$ (11,339)$ (8,868)$ (30,934)$ (18,588)
Net loss per share attributable to common stockholders, basic$ (0.59)$ (3.35)$ (2.21)$ (7.06)
Net loss per share attributable to common stockholders, diluted$ (0.59)$ (3.35)$ (2.21)$ (7.06)
Weighted-average number of shares used in computing net loss per share, basic19,347,1482,643,87913,987,8622,632,919
Weighted-average number of shares used in computing net loss per share, diluted19,347,1482,643,87913,987,8622,632,919
Other comprehensive income (loss):    
Unrealized loss on investments$ (181)$ (3)$ (514)$ (3)
Comprehensive loss$ (11,520)$ (6,946)$ (29,628)$ (14,001)

ANTX Balance Sheet

2022-09-30
CONDENSED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 28,802$ 12,097
Short-term investments75,58046,458
Prepaid expenses and other current assets2,8411,551
Right-of-use asset, net73 
Total current assets107,29660,106
Deferred offering costs 1,724
Long-term investments1,9923,486
Other assets, long-term720 
Total assets110,00865,316
Current liabilities:  
Accounts payable1,4401,063
Accrued compensation1,106916
Accrued liabilities1,8051,399
Operating lease liabilities73 
Options subject to repurchase, short-term817
Total current liabilities4,4323,395
Options subject to repurchase, long-term313
Total liabilities4,4353,408
Commitments and contingencies (Note 8)
Redeemable convertible preferred stock: $0.00001 par value; 0 and 11,409,536 shares authorized at September 30, 2022 and December 31, 2021, respectively, 0 and 11,409,488 shares issued and outstanding at September 30, 2022 and December 31, 2021; aggregate liquidation preference $0 and $103,064 at September 30, 2022 and December 31, 2021, respectively 109,319
Stockholders' equity (deficit):  
Preferred stock, $0.00001 par value; 10,000,000 and 0 shares authorized at September 30, 2022 and December 31, 2021, respectively; no shares issued and outstanding at September 30, 2022 and December 31, 2021
Common stock, $0.00001 par value; 500,000,000 and 17,166,642 shares authorized at September 30, 2022 and December 31, 2021, respectively; 19,402,658 and 2,730,298 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively
Additional paid-in capital183,995 
Accumulated other comprehensive loss(541)(27)
Accumulated deficit(77,881)(47,384)
Total stockholders' equity (deficit)105,573(47,411)
Total liabilities, redeemable convertible preferred stock, and stockholders' equity110,00865,316
Redeemable Convertible Preferred Stock  
Current liabilities:  
Redeemable convertible preferred stock: $0.00001 par value; 0 and 11,409,536 shares authorized at September 30, 2022 and December 31, 2021, respectively, 0 and 11,409,488 shares issued and outstanding at September 30, 2022 and December 31, 2021; aggregate liquidation preference $0 and $103,064 at September 30, 2022 and December 31, 2021, respectively$ 109,319